Tags

Type your tag names separated by a space and hit enter

Bacterial mutagenic evaluation of Luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His- and the Escherichia coli Tryp- reversion tests.
Mutagenesis. 1996 Jan; 11(1):27-31.M

Abstract

Luxabendazole is a new benzimidazole carbamate chemotherapeutic agent, which has proved to be effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes. The mutagenic properties of Luxabendazole were investigated in the in vitro Ames Salmonella and E. coli tests. The product was tested at concentrations of 0.5, 5, 50, 500, 1250 and 2500 micrograms/plate in the TA1535, TA1538, TA98 and TA100 strains of Salmonella typhimurium, and 0.5, 5, 50 and 500 micrograms/plate in the WP2, WP2uvrA- and its pKM 101-containing derivative CM891 (WP2 uvrA- pKM101) strains of Escherichia coli, with and without S9 microsomal activation (post-mitochondrial liver fraction from Wistar rats pretreated with Aroclor(R)). Positive and negative controls were included in each experiment. From the present study it can be concluded that Luxabendazole, over a dose range of 0.5-2500 micrograms/plate, is unlikely to present a mutagenic hazard, as demonstrated by the Ames test.

Links

Publisher Full Text

Authors+Show Affiliations

Ortiz AI
Departamento de Fisiologá, Farmacología y Toxicologia, Facultad de Veterinaria, Universidad de Leon, Spain.
Pollastrini MT
No affiliation info available
Barea M
No affiliation info available
Ordóñez D
No affiliation info available

MeSH

AnimalsAnthelminticsBenzimidazolesBiotransformationCarbamatesEscherichia coliHumansIn Vitro TechniquesMaleMicrosomes, LiverMutagenicity TestsMutagensRatsRats, Sprague-DawleySalmonella typhimurium

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

8671711

Citation

Ortiz, A I., et al. "Bacterial Mutagenic Evaluation of Luxabendazole, a New Broad Spectrum Anthelmintic, With the Salmonella Typhimurium His- and the Escherichia Coli Tryp- Reversion Tests." Mutagenesis, vol. 11, no. 1, 1996, pp. 27-31.
Ortiz AI, Pollastrini MT, Barea M, et al. Bacterial mutagenic evaluation of Luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His- and the Escherichia coli Tryp- reversion tests. Mutagenesis. 1996;11(1):27-31.
Ortiz, A. I., Pollastrini, M. T., Barea, M., & Ordóñez, D. (1996). Bacterial mutagenic evaluation of Luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His- and the Escherichia coli Tryp- reversion tests. Mutagenesis, 11(1), 27-31.
Ortiz AI, et al. Bacterial Mutagenic Evaluation of Luxabendazole, a New Broad Spectrum Anthelmintic, With the Salmonella Typhimurium His- and the Escherichia Coli Tryp- Reversion Tests. Mutagenesis. 1996;11(1):27-31. PubMed PMID: 8671711.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bacterial mutagenic evaluation of Luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His- and the Escherichia coli Tryp- reversion tests. AU - Ortiz,A I, AU - Pollastrini,M T, AU - Barea,M, AU - Ordóñez,D, PY - 1996/1/1/pubmed PY - 1996/1/1/medline PY - 1996/1/1/entrez SP - 27 EP - 31 JF - Mutagenesis JO - Mutagenesis VL - 11 IS - 1 N2 - Luxabendazole is a new benzimidazole carbamate chemotherapeutic agent, which has proved to be effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes. The mutagenic properties of Luxabendazole were investigated in the in vitro Ames Salmonella and E. coli tests. The product was tested at concentrations of 0.5, 5, 50, 500, 1250 and 2500 micrograms/plate in the TA1535, TA1538, TA98 and TA100 strains of Salmonella typhimurium, and 0.5, 5, 50 and 500 micrograms/plate in the WP2, WP2uvrA- and its pKM 101-containing derivative CM891 (WP2 uvrA- pKM101) strains of Escherichia coli, with and without S9 microsomal activation (post-mitochondrial liver fraction from Wistar rats pretreated with Aroclor(R)). Positive and negative controls were included in each experiment. From the present study it can be concluded that Luxabendazole, over a dose range of 0.5-2500 micrograms/plate, is unlikely to present a mutagenic hazard, as demonstrated by the Ames test. SN - 0267-8357 UR - https://www.unboundmedicine.com/medline/citation/8671711/Bacterial_mutagenic_evaluation_of_Luxabendazole_a_new_broad_spectrum_anthelmintic_with_the_Salmonella_typhimurium_His__and_the_Escherichia_coli_Tryp__reversion_tests_ L2 - https://academic.oup.com/mutage/article-lookup/doi/10.1093/mutage/11.1.27 DB - PRIME DP - Unbound Medicine ER -